Cell Source, Inc. (CLCS) Financial Statements (2024 and earlier)

Company Profile

Business Address 57 WEST 57TH STREET
NEW YORK, NY 10019
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments222,66593,095245,11927,90818,934371,048
Cash and cash equivalents222,66593,095245,11927,90818,934371,048
Prepaid expense164,175203,750177,56957,19638,926124,693
Other current assets23,00516,92229,65129,6797,93235,936
Total current assets:409,845313,767452,339114,78365,792531,677
Noncurrent Assets
Property, plant and equipment     (2,582)(2,582)
Other undisclosed noncurrent assets      2,582
Total noncurrent assets:     (2,582) 
Other undisclosed assets     2,582 
TOTAL ASSETS:409,845313,767452,339114,78365,792531,677
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,166,1821,920,2512,182,4301,326,989952,540201,824
Interest and dividends payable600,189697,17811,84613,563108,562
Taxes payable 122,457118,017116,401147,082
Employee-related liabilities 9,7509,75012,000 
Accounts payable680,325223,041193,095135,415277,786 
Accrued liabilities1,485,8571,097,0211,159,9501,051,961532,790821,244
Other undisclosed accounts payable and accrued liabilities      (875,064)
Debt1,676,4374,512,8381,238,0001,111,7081,463,0001,173,674
Deferred compensation liability849,898766,102724,185660,863587,734626,758
Derivative instruments and hedges, liabilities    351,900200,500628,200
Due to related parties150,000150,000150,000150,000222,000150,000
Other liabilities    235,500100,000100,000
Other undisclosed current liabilities  2,790,7114,105,1061,874,764 2,208,595
Total current liabilities:4,842,51710,139,9028,399,7215,711,7243,525,7745,089,051
Noncurrent Liabilities
Long-term debt and lease obligation 6,077,770     
Long-term debt, excluding current maturities 6,077,770     
Other undisclosed noncurrent liabilities    145,000  
Total noncurrent liabilities: 6,077,770  145,000  
Other undisclosed liabilities2,123,453   1,460,189 
Total liabilities:13,043,74010,139,9028,399,7215,856,7244,985,9635,089,051
Equity
Equity, attributable to parent, including:(12,633,895)(9,826,135)(7,947,382)(5,741,941)(4,920,171)(4,557,374)
Preferred stock   1,342  644
Common stock36,08234,36132,53827,07726,07825,349
Additional paid in capital23,674,35421,316,31817,724,73115,375,56511,723,2249,969,520
Accumulated deficit(36,346,176)(31,178,428)(25,705,993)(21,145,828)(16,670,333)(14,552,887)
Other undisclosed equity, attributable to parent1,8451,614 1,245860 
Total equity:(12,633,895)(9,826,135)(7,947,382)(5,741,941)(4,920,171)(4,557,374)
TOTAL LIABILITIES AND EQUITY:409,845313,767452,339114,78365,792531,677

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(4,175,333)(4,018,572)(3,638,036)(3,902,663)(2,006,143)(2,292,803)
Operating loss:(4,175,333)(4,018,572)(3,638,036)(3,902,663)(2,006,143)(2,292,803)
Nonoperating expense(992,415)(1,453,863)(922,129)(572,832)(111,303)(789,707)
Investment income, nonoperating   16,977 (209,655) 
Interest and debt expense(170,868)(629,201)134,202194,245(191,251)(725,355)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   (134,202)(194,245)(260,032)484,796
Loss from continuing operations before equity method investments, income taxes:(5,338,616)(6,101,636)(4,560,165)(4,475,495)(2,568,729)(3,323,069)
Other undisclosed income from continuing operations before income taxes170,868629,202    
Loss from continuing operations before income taxes:(5,167,748)(5,472,434)(4,560,165)(4,475,495)(2,568,729)(3,323,069)
Income tax expense (benefit) 754,6601,771,9022,424,4232,524,179717,000(22,000)
Other undisclosed income from continuing operations      
Loss from continuing operations:(4,413,088)(3,700,532)(2,135,742)(1,951,316)(1,851,729)(3,345,069)
Loss before gain (loss) on sale of properties:(3,700,532)(2,135,742)(1,951,316)(1,851,729)(3,345,069)
Other undisclosed net loss  (1,771,903) (2,524,179)  
Net loss:(4,413,088)(5,472,435)(2,135,742)(4,475,495)(1,851,729)(3,345,069)
Other undisclosed net income (loss) attributable to parent(754,660) (2,424,423) (265,717)262,559
Net loss attributable to parent:(5,167,748)(5,472,435)(4,560,165)(4,475,495)(2,117,446)(3,082,510)
Preferred stock dividends and other adjustments(1,157,486)(973,205)    
Other undisclosed net loss available to common stockholders, basic   (877,736)(741,981)  
Net loss available to common stockholders, diluted:(6,325,234)(6,445,640)(5,437,901)(5,217,476)(2,117,446)(3,082,510)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(4,413,088)(5,472,435)(2,135,742)(4,475,495)(1,851,729)(3,345,069)
Comprehensive loss, net of tax, attributable to parent:(4,413,088)(5,472,435)(2,135,742)(4,475,495)(1,851,729)(3,345,069)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: